RC18 (TACI-CAML interactor antibody fusion protein)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RC18 (TACI-CAML interactor antibody fusion protein), covering 2023-10-11 to 2023-10-11. Get the full timeline:
Most recent: Clinical Trial Update: A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis [Phase 2]